| Followers | 245 |
| Posts | 13889 |
| Boards Moderated | 0 |
| Alias Born | 05/19/2015 |
Thursday, July 07, 2022 8:44:59 AM
$RGBP $RGBPP WE ARE THE ONLY ONES THAT KNOW ABOUT THE PATENT THAT WAS AWARDED. TOTAL GAME CHANGER. #MRNA CANCER VACCINES$I
Whoo Hooo!
https://www.yahoo.com/news/medical-breakthrough-offers-promise-cancer-110209912.html
We all seen the RGBP run to over 8 cent$ last August when this patent was awarded. Now we hear More!
https://patents.justia.com/assignee/regen-biopharma-inc
Regen BioPharma Inc (OTCMKTS: RGBP) is making a powerful run up the charts after the Company’s Cancer Vaccine Patent was approved August 17th 2021 Exclusively for RGBP which will be announced once the Company uplists to “pink current” According to the USPTO: Antigen specific mRNA cellular cancer vaccines are cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
https://www.prnewswire.com/news-releases/regen-biopharma-inc-to-initiate-development-of-its-modified-mrna-anti-cancer-vaccine-technology-301480653.html
Whoo Hooo!
https://www.yahoo.com/news/medical-breakthrough-offers-promise-cancer-110209912.html
We all seen the RGBP run to over 8 cent$ last August when this patent was awarded. Now we hear More!
https://patents.justia.com/assignee/regen-biopharma-inc
Regen BioPharma Inc (OTCMKTS: RGBP) is making a powerful run up the charts after the Company’s Cancer Vaccine Patent was approved August 17th 2021 Exclusively for RGBP which will be announced once the Company uplists to “pink current” According to the USPTO: Antigen specific mRNA cellular cancer vaccines are cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
https://www.prnewswire.com/news-releases/regen-biopharma-inc-to-initiate-development-of-its-modified-mrna-anti-cancer-vaccine-technology-301480653.html
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
